<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>cancer therapies on FinanClub</title>
    <link>https://finan.club/tags/cancer-therapies/</link>
    <description>Recent content in cancer therapies on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Feb 2024 09:04:12 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cancer-therapies/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Fri, 09 Feb 2024 09:04:12 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:33
Chances: Iovance&amp;rsquo;s lead pipeline drug is anticipated to receive FDA approval as the first individualized, one-time cell therapy for certain patients with melanoma. The company is focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.</description>
    </item>
    
  </channel>
</rss>
